Literature DB >> 33660057

Clinical predictors and sequelae of computed tomography defined leaflet thrombosis following transcatheter aortic valve replacement at medium-term follow-up.

Hashrul N Rashid1, Michael Michail1,2, Abdul R Ihdayhid1,3, Cameron Dowling1, Nancy Khav1, Sean Tan1, Jaineel Ramnarain1, James D Cameron1, Arthur Nasis1, Stephen J Nicholls1, Robert P Gooley4.   

Abstract

BACKGROUND: The clinical predictors and sequelae of leaflet thrombosis (LT) following transcatheter aortic valve replacement (TAVR) is still unclear. Therefore, our aim was to determine the clinical predictors and sequelae at mid-term follow-up of computed tomography (CT)-defined LT following TAVR. METHODS AND
RESULTS: We performed a prospective evaluation with a 320-multislice CT following TAVR for the presence of LT, defined as hypo-attenuated leaflet thickening (HALT). Four-dimensional CT image-rendering was performed to determine the presence of reduced leaflet motion (RELM). 172 patients [89 (51.7%) male, mean age 82.8 ± 5.7 years] treated with commercially available TAVR device (Lotus 54%, CoreValve 32% and Sapien 3 14%) were included, with median CT-scan at 6.0 weeks post-TAVR. Prevalence of HALT was 14.0% (24 cases) and RELM was 9.8% (17 cases). On multivariate analysis, patients with HALT were less prescribed oral anticoagulation (OAC) (OR 9.9), received larger TAVR prostheses (OR 5.7) and higher rates of moderate-severe para-valvular regurgitation (PVR) (OR 16.3). There was no difference in clinical outcomes at a median follow-up of 2.3 years. Patients with RELM had significantly higher transvalvular gradients after discharge when compared to those without RELM.
CONCLUSIONS: Absence of OAC, large TAVR prostheses and moderate-severe PVR were predictors for LT. Transvalvular gradients were higher in patients that developed RELM but not HALT. Further studies are warranted to determine the long-term impact of LT on TAVR durability. Prevalence of different sub-types of CT-defined LT (HALT and RELM) and the clinical predictors of developing LT following TAVR. CT computed tomography, HALT hypo-attenuated leaflet thickening, LT leaflet thrombosis, RELM reduced leaflet motion, TAVR transcatheter aortic valve replacement.
© 2021. Crown.

Entities:  

Keywords:  Hypo-attenuated leaflet thickening; Leaflet thrombosis; Reduced leaflet motion; TAVI; TAVR

Mesh:

Year:  2021        PMID: 33660057     DOI: 10.1007/s00380-021-01803-4

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  7 in total

1.  Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA.

Authors:  Aditya Bharadwaj; Jessica Potts; Mohamed O Mohamed; Purvi Parwani; Pooja Swamy; Juan C Lopez-Mattei; Muhammad Rashid; Chun Shing Kwok; David L Fischman; Vassilios S Vassiliou; Philip Freeman; Erin D Michos; Mamas A Mamas
Journal:  Eur Heart J       Date:  2020-06-14       Impact factor: 29.983

2.  Thrombogenic potential of transcatheter aortic valve implantation with trivial paravalvular leakage.

Authors:  Lawrence N Scotten; Rolland Siegel
Journal:  Ann Transl Med       Date:  2014-05

3.  Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR.

Authors:  Ryo Yanagisawa; Kentaro Hayashida; Yoshitake Yamada; Makoto Tanaka; Fumiaki Yashima; Taku Inohara; Takahide Arai; Takashi Kawakami; Yuichiro Maekawa; Hikaru Tsuruta; Yuji Itabashi; Mitsushige Murata; Motoaki Sano; Kazuma Okamoto; Akihiro Yoshitake; Hideyuki Shimizu; Masahiro Jinzaki; Keiichi Fukuda
Journal:  JACC Cardiovasc Imaging       Date:  2016-12-08

4.  Valve thrombosis following transcatheter aortic valve replacement: significance of blood stasis on the leaflets.

Authors:  Koohyar Vahidkhah; Mohammed Barakat; Mostafa Abbasi; Shahnaz Javani; Peyman N Azadani; Anwar Tandar; Danny Dvir; Ali N Azadani
Journal:  Eur J Cardiothorac Surg       Date:  2017-05-01       Impact factor: 4.191

5.  Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.

Authors:  Philippe Pibarot; Julien Ternacle; Wael A Jaber; Erwan Salaun; Abdellaziz Dahou; Federico M Asch; Neil J Weissman; Leonardo Rodriguez; Ke Xu; Mohamed-Salah Annabi; Ezequiel Guzzetti; Jonathan Beaudoin; Mathieu Bernier; Jonathon Leipsic; Philipp Blanke; Marie-Annick Clavel; Erin Rogers; Maria C Alu; Pamela S Douglas; Raj Makkar; D Craig Miller; Samir R Kapadia; Michael J Mack; John G Webb; Susheel K Kodali; Craig R Smith; Howard C Herrmann; Vinod H Thourani; Martin B Leon; Rebecca T Hahn
Journal:  J Am Coll Cardiol       Date:  2020-10-20       Impact factor: 24.094

6.  The role of four-dimensional computed tomography in transcatheter aortic valve replacement prosthesis endocarditis with concurrent leaflet thrombosis: a case report.

Authors:  Nancy Khav; Hashrul N Rashid; Adam J Brown
Journal:  Eur Heart J Case Rep       Date:  2020-09-04
  7 in total
  1 in total

1.  Subclinical leaflet thrombosis after transcatheter aortic valve replacement and anticoagulant treatment: lights and shadows.

Authors:  Francesco Condello; Matteo Sturla; Riccardo Terzi
Journal:  J Thromb Thrombolysis       Date:  2021-09-23       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.